Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7376-7379

  Manetti, Fabrizio ^a   Castagnolo, Daniele ^a   Raffi, Francesco ^a   Zizzari, Alessandra T ^a   Rajamaki, Suvi ^a   D'Arezzo, Silvia ^b   Visca, Paolo ^b,c   Cona, Alessandra ^c   Fracasso, Maria Enrica ^d   Doria, Denise ^d   Posteraro, Brunella ^e   Sanguinetti, Maurizio ^e   Fadda, Giovanni ^e   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c ROMA TRE UNIVERSITY   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GUANIDINE DERIVATIVE; GUANIDINECARBOXAMIDE DERIVATIVE; ITRACONAZOLE; MACROCYCLIC COMPOUND; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; STRUCTURE ACTIVITY RELATION;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DRUG DESIGN; GUANIDINE; HUMANS; MACROCYCLIC COMPOUNDS; MICROBIAL SENSITIVITY TESTS; UREA;

EID: 72249115121     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900760k     Document Type: Article

References (19)

1. Chamilos, G.; Kontoyiannis, D. P. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Curr. Opin. Infect. Dis. 2006, 19, 380-385.
2. Klepser, M. E. Candida resistance and its clinical relevance. Pharmacotherapy 2006, 26, 68S-75S.
3. (a) Aperis, G.; Myriounis, N.; Spanakis, E. K.; Mylonakis, E. Develop in the treatment of candidiasis: more choices and new challenges. Expert Opin. Invest. Drugs 2006, 15, 1319-1336.
4. (b) Hoffman, H. L.; Ernst, E. J.; Klepser,M. E. Novel triazole antifungal agents. Expert Opin. Invest. Drugs 2000, 9, 593-605.
5. Pauli, A. Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils. Med. Res. Rev. 2006, 26, 223-268.
6. (a) Buxbaum, A.; Kratzer, C.; Graninger, W.; Georgopoulos, A. Antimicrobial and toxicological profile of the new biocide Akacid plus. J. Antimicrob. Chemother. 2006, 58, 193-197.
7. (b) Jana, G. H.; Jain, S.; Arora, S. K.; Sinha, N. Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents. Bioorg. Med. Chem. Lett. 2005, 15, 3592-3595.
8. (c) Martin, D. W.; Schurr, M. J.; Mudd, M. H.; Govan, J. R.; Holloway, B.W.; Deretic, V. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8377-8381.
9. Guazatine produces severe local irritation, and single oral doses are of moderate toxicity, with an oral LD50 value in rats of 280 mg/kg body weight. In a number of short term studies in rats, the overall NOAEL of guazatine was 200 ppm, equivalent to 10 mg/kg bw per day. In a 1-year study in dogs, the NOAEL was 25 ppm, equal to 0.8 mg/kg bw per day. Several studies in rats concluded that guazatine is not genotoxic and carcinogenic, while in a study of developmental toxicity in rabbits there were no signs of fetotoxicity or teratogenicity. FAO Corporate Document Repository.
10. Dreassi, E.; Zizzari, A. T.; D'Arezzo, S.; Visca, P.; Botta, M. Analysis of guazatine mixture by LC and LC-MSand antimycotic activity determination of principal components. J. Pharm. Biomed. Anal. 2007, 46, 1499-1506.
11. Delle Monache, G.; Botta, B.; Delle Monache, F.; Espinal, R.; De Bonnevaux, S. C.; De Luca, C.; Botta, M.; Corelli, F.; Carmignani, M. Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide. J. Med. Chem. 1993, 36, 2956-2963.
12. (a) Dodd, D. S.; Kozikowski, A. P. Conversion of alcohols to protected guanidines using the Mitsunobu protocol. Tetrahedron Lett. 1994, 35, 977-980.
13. (b) Corelli, F.; Dei, D.; Delle Monache, G.; Botta, B.; De Luca, C.; Botta, M.; Volpe, A. R.; Carmignani, M. Synthesis and preliminary pharmacological evaluation of analogues of caracasanamide, a hypotensive natural product. Bioorg. Med. Chem. Lett. 1996, 6, 653-658.
14. (c) Cona, A.; Manetti, F.; Leone, R.; Corelli, F.; Tavladoraki, P.; Polticelli, F.; Botta, M. Molecular basis for the binding of competitive inhibitors of maize polyamino oxidase. Biochemistry 2004, 43, 3426-3435.
15. Castagnolo, D.; Raffi, F.; Giorgi, G.; Botta, M. Macrocyclization of di-Boc-guanidino-alkylamines related to guazatine components: discovery and synthesis of innovative macrocyclic amidinoureas. Eur. J. Org. Chem. 2009, 3, 334-337.
16. For further details, see Supporting Information.
17. The low MIC50 value (0.8 μM) of fluconazole toward C. albicans ATCC 60193 was in disagreement with literature reports showing such a strain as fluconazole-resistant ( Carballeira, N. M.; Sanabria, D.;Cruz,C.;Parang,K.;Wan, B.;Franzblau, S. 2,6-Hexadecadiynoic acid and 2,6-nonadecadiynoic acid: novel synthesized acetylenic fatty acids as potent antifungal agents. Lipids 2006, 41, 507-511). However, determination of the MIC80 value (>418 μM) allowed us to classify the strain as fluconazole-resistant, according to the literature .
18. Drug toxicity, particularly nephrotoxicity, is a significant problem, as amphotericin B also damages mammalian cell membranes.
19. Kyle, A. A.; Dahl, M. V. Topical therapy for fungal infections. Am. J. Clin. Dermatol. 2004, 5, 443-451.